Highlights
- CF33-hNIS (VAXINIA) technology has been selected for an oral presentation at the Cholangiocarcinoma Foundation Annual Conference on 18 April2024.
- IMU will also showcase a poster during the conference.
- The conference is scheduled from 17 to 19 April 2024, at the Salt Palace Convention Center in Salt Lake City, Utah.
Imugene Limited (ASX: IMU) has announced its participation in the 2024 Cholangiocarcinoma Foundation Annual Conference. The company’s CF33-hNIS (VAXINIA) technology has been selected for an oral presentation at the conference during the Basic Science Research Seminar Abstract Session, scheduled for 18 April 2024. Additionally, the company will showcase a poster during the conference.
More about the presentation
The title of the abstract is –
The research findings suggest that CF33-hNIS monotherapy could serve as a viable and safe treatment choice for gastrointestinal malignancies, including cholangiocarcinoma, a rare condition that lacks sufficient medical treatments.
Cholangiocarcinoma is an uncommon and aggressive cancer that develops in the bile ducts. Due to its aggressive nature and difficulty in early detection, the prognosis for cholangiocarcinoma can often be unfavourable. These factors highlight the need for research and advancements in its treatment.
IMU shares traded at AU$0.110 apiece at the time of writing on 3 April 2024.